Segment Information - Summary of Company's Financial Data for Development and Commercialization of Pharmaceutical Products Segment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Net product sales	$ 10,249,415	$ 5,180,630
Cost of goods sold	356,531	201,879
Eversana profit sharing	15,080,699	12,227,735
Interest income	353,313	138,596
Interest expense (non-cash)	501,370	500,000
Pharmaceutical Products [Member]
Segment Reporting Information [Line Items]
Net product sales	10,249,415	5,180,630
Cost of goods sold	(356,531)	(201,879)
Eversana profit sharing	(8,733,347)	(4,401,590)
Employee expenses	(2,481,056)	(3,188,601)
Professional fees	(2,059,591)	(2,553,662)
Stock-based compensation	(773,121)	(1,128,109)
Sales and marketing expenses	(750,272)	(659,535)
Other operating expenses	(299,634)	(478,145)
Interest income	353,313	138,596
Interest expense (non-cash)	(501,370)	(500,000)
Total segment costs loss and net loss	$ (5,352,194)	$ (7,792,295)